locally advanced Non-small cell Lung Cancer
Conditions
Interventions
Combination of biweekly calboplatin:AUC=4 plus nab-paclitaxel(100mg/m)with concurrent thoracic radiotherapy 2Gy/day for 30 times
Sponsors
Hirosaki University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patient with pathologically or cytologically proven non-small cell lung cancer 2) Patient with stage IIIA or IIIB desease 3) Patient who has not been previously treated for lung cancer, including chemotherapy, radiotherapy, and operation 4) V20 < 35% 5) Patient who has at least one or more measurable lesion 6) ECOG performance status (PS): 0-1 7) Patient aged 20-74 years old 8) Adequate organ function. 9) Patient who are considered to survive for more than 3 months. 10) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) T3N1 2) Superior vena cava syndrome. 3) Lymph node metastases of opposite side hilum, malignant pleuritis, malignant pericarditis, lymphangitis. 4) With active double cancer. 5) Active infection. 6) Other serious disease condition (idiopathic pulmonary fibrosis, interstitial lung disease, renal failure, liver failure, Cerebral Vascular Disorder, unstable angina, cardiac infarction, Myocardial Infarction, poorly controlled diabetes mellitus,etc). 7) Grade2< peripheral neuropathy. 8) Severe drug allergy. 9) Pregnancy or lactation. 10) Patient whose participation in the trial is judged to be inappropriate by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate, Progression free survival, Over all survival, Adverse events | — |
Countries
Japan
Contacts
Public ContactHisashi Tanaka
Hirosaki University Graduate School of Medicine Department of Respiratory Medicine
Outcome results
None listed